| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 2051* | 2020 |
| Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine C Pauli, BD Hopkins, D Prandi, R Shaw, T Fedrizzi, A Sboner, V Sailer, ... Cancer discovery 7 (5), 462-477, 2017 | 956 | 2017 |
| Whole-exome sequencing of metastatic cancer and biomarkers of treatment response H Beltran, K Eng, JM Mosquera, A Sigaras, A Romanel, H Rennert, ... JAMA oncology 1 (4), 466-474, 2015 | 321 | 2015 |
| Clinical features of neuroendocrine prostate cancer V Conteduca, C Oromendia, KW Eng, R Bareja, M Sigouros, A Molina, ... European journal of cancer 121, 7-18, 2019 | 305 | 2019 |
| Clonal evolution of chemotherapy-resistant urothelial carcinoma BM Faltas, D Prandi, ST Tagawa, AM Molina, DM Nanus, C Sternberg, ... Nature genetics 48 (12), 1490-1499, 2016 | 300 | 2016 |
| A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns W Jiao, G Atwal, P Polak, R Karlic, E Cuppen, A Danyi, J de Ridder, ... Nature communications 11 (1), 728, 2020 | 205 | 2020 |
| Recurrence patterns after open and robot-assisted radical cystectomy for bladder cancer DP Nguyen, BAH Al Awamlh, X Wu, P O’Malley, IM Inoyatov, ... European urology 68 (3), 399-405, 2015 | 204 | 2015 |
| Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling BD Robinson, PJ Vlachostergios, B Bhinder, W Liu, K Li, TJ Moss, ... Nature communications 10 (1), 2977, 2019 | 195 | 2019 |
| Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes JJ Meeks, H Al-Ahmadie, BM Faltas, JA Taylor III, TW Flaig, DJ DeGraff, ... Nature Reviews Urology 17 (5), 259-270, 2020 | 155 | 2020 |
| Sacituzumab govitecan, a novel antibody–drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma B Faltas, DM Goldenberg, AJ Ocean, SV Govindan, F Wilhelm, ... Clinical Genitourinary Cancer 14 (1), e75-e79, 2016 | 113 | 2016 |
| Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA N Agarwal, SK Pal, AW Hahn, RH Nussenzveig, GR Pond, SV Gupta, ... Cancer 124 (10), 2115-2124, 2018 | 101 | 2018 |
| Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study. ST Tagawa, BM Faltas, ET Lam, PJ Saylor, A Bardia, J Hajdenberg, ... Journal of Clinical Oncology 37 (7_suppl), 354-354, 2019 | 91 | 2019 |
| Molecular characterization of upper tract urothelial carcinoma in the era of next-generation sequencing: a systematic review of the current literature MR Hassler, F Bray, JWF Catto, AP Grollman, A Hartmann, V Margulis, ... European urology 78 (2), 209-220, 2020 | 86 | 2020 |
| Sex differences in oncogenic mutational processes CH Li, SD Prokopec, RX Sun, F Yousif, N Schmitz, PC Boutros Nature communications 11 (1), 4330, 2020 | 81 | 2020 |
| Cornering metastases: therapeutic targeting of circulating tumor cells and stem cells B Faltas Frontiers in oncology 2, 68, 2012 | 69 | 2012 |
| Personalized In vitro and C Pauli, BD Hopkins, D Prandi, R Shaw, T Fedrizzi, A Sboner, V Sailer, ... Vivo Cancer Models to Guide Precision Medicine, In: Cancer Discov. 2017; 7 …, 2017 | 65 | 2017 |
| Treatment resistance in urothelial carcinoma: an evolutionary perspective PJ Vlachostergios, BM Faltas Nature reviews Clinical oncology 15 (8), 495-509, 2018 | 64 | 2018 |
| Next-generation rapid autopsies enable tumor evolution tracking and generation of preclinical models DJ Pisapia, S Salvatore, C Pauli, E Hissong, K Eng, D Prandi, VW Sailer, ... JCO precision oncology 1, 1-13, 2017 | 53 | 2017 |
| Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers JP Sfakianos, J Daza, Y Hu, H Anastos, G Bryant, R Bareja, KK Badani, ... Nature communications 11 (1), 2540, 2020 | 51 | 2020 |
| Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview AKB Alme, BS Karir, BM Faltas, CG Drake Urologic Oncology: Seminars and Original Investigations 34 (4), 171-181, 2016 | 50 | 2016 |
